Black Diamond Therapeutics, Inc. - Common Stock (BDTX)

Q1 2021 13F Holders as of 3/31/2021

Type / Class
Equity / Common Stock
Shares outstanding
56.1M
Number of holders
109
Total 13F shares, excl. options
29.1M
Shares change
+511K
Total reported value, excl. options
$706M
Value change
-$7.56M
Put/Call ratio
1.1
Number of buys
56
Number of sells
-50
Price
$24.26

Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q1 2021

133 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q1 2021.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29.1M shares of 56.1M outstanding shares and own 51.86% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (3.45M shares), RA CAPITAL MANAGEMENT, L.P. (2.59M shares), Bellevue Group AG (2.24M shares), FMR LLC (2.09M shares), BOXER CAPITAL, LLC (2.01M shares), BlackRock Inc. (1.93M shares), VANGUARD GROUP INC (1.88M shares), STATE STREET CORP (1.79M shares), Artal Group S.A. (1.65M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.05M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.